aeglea生物制藥(agle):孕期心理
孕期心理描述::Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-22-021529 Act: 34 Size: 9 MB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, item 5.02 Accession Number: 0001193125-22-294899 Act: 34 Size: 151 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-047651 Size: 5 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, items 5.02 and 8.01 Accession Number: 0001193125-22-229043 Act: 34 Size: 165 KB 網頁鏈接
全球新藥浪潮:
AGLE Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 DeficiencyAeglea生物制藥(AGLE)
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-059262 Size: 5 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-059261 Size: 6 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, items 5.03 and 9.01 Accession Number: 0001193125-22-308316 Act: 34 Size: 355 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0000950170-22-021527 Act: 34 Size: 4 MB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, item 8.01 Accession Number: 0001193125-22-224107 Act: 34 Size: 151 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, item 8.01 Accession Number: 0001193125-22-257184 Act: 34 Size: 148 KB 網頁鏈接
產業鏈觀察:
藥聞▶2022年8月18日,臨床階段的生物技術公司Aeglea生物制藥(AGLE)今天宣布,用于治療精氨酸酶1缺陷(ARG1-D)的pegzilarginase市場授權申請(MAA)已經提交給歐洲藥品管理局(EMA)并成功通過驗證。該MAA是由Aeglea在歐洲和中東的商業化合作伙伴Imedica Pharma AB提交的。Pegzilarginase是一種新型的重組人精氨酸酶1,在臨床試驗中被證明可以使ARG1-D患者的氨基酸精氨酸水平正常化,ARG1-D是一種以高精氨酸水平為特征的罕見漸進性疾病。患有ARG1-D的人經歷了與痙攣有關的嚴重行動限制、癲癇發作、發育遲緩、智力障礙和早期死亡。
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-047648 Size: 5 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-047649 Size: 5 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-047653 Size: 4 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-047656 Size: 5 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-22-239029 Act: 34 Size: 16 MB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001319244-22-000177 Act: 34 Size: 95 KB 網頁鏈接
Aeglea生物制藥(AGLE):
Aeglea生物制藥(AGLE) 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-047655 Size: 9 KB 網頁鏈接